Futura Medical PLC (GB:FUM)
LSE:FUM
Want to see GB:FUM full AI Analyst Report?
Top Page
Futura Medical
(LSE:FUM)
Select Model
Select Model
Rating:41Neutral
Price Target:
0.52 p
▼(-57.89% Downside)
Action:Reiterated
Date:05/29/26
Overall score is held down primarily by deteriorating financial performance (steep 2025 revenue drop, significant losses, and persistent negative free cash flow) and bearish technicals (price below key moving averages with negative MACD). Valuation is not a meaningful offset due to the negative P/E and no dividend yield data.
Positive Factors
Conservative balance sheet (no debt)
Zero reported debt is a durable structural strength: it lowers bankruptcy and interest-rate exposure, preserves strategic optionality for licensing or selective investments, and reduces near-term refinancing pressure. This bolsters financial flexibility over the next several months.
Negative Factors
Severe revenue decline in 2025
A ~79% revenue collapse and swing to a material net loss reflect structural volatility in commercialisation progress or partner execution. This undermines earnings visibility, strains retained capital, and can impair negotiation leverage with potential licensees or distributors over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet (no debt)
Zero reported debt is a durable structural strength: it lowers bankruptcy and interest-rate exposure, preserves strategic optionality for licensing or selective investments, and reduces near-term refinancing pressure. This bolsters financial flexibility over the next several months.
Read all positive factors
Futura Medical (FUM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£3.14M
Dividend YieldN/A
Average Volume (3M)3.22M
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue Growth-87.82%
EPS Growth-746.51%
CountryUK
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding581,327,760
10 Day Avg. Volume4,828,957
30 Day Avg. Volume3,220,377
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.30
Price to Sales (P/S)2.15
P/FCF Ratio-0.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£5.10M
Futura Medical Business Overview & Revenue Model
Company Description
Futura Medical plc operates as a pharmaceutical firm specializing in the creation and advancement of consumer healthcare products. The company primarily targets the sexual health and pain management sectors. Its leading innovation is MED3000, a to...
How the Company Makes Money
Futura Medical makes money primarily by commercialising its erectile dysfunction product MED3000/Eroxon through partnerships rather than building a large direct sales infrastructure. Its core revenue model is partner-led: the company grants commer...
Futura Medical Earnings Call Summary
Earnings Call Date:Sep 30, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Sep 22, 2026
Earnings Call Sentiment Negative
The earnings call reflected significant financial and operational challenges with revenue shortfalls, unexpected market performance, and inventory issues. While there are promising R&D developments, these are long-term. Immediate financial pressures and market challenges dominate the current outlook.Positive Updates
R&D Developments
Futura is advancing two new products: Project Intense and WSD4000. Project Intense aims to enhance sensorial effects for men, with regulatory approval expected by the end of 2025. WSD4000 targets women's sexual response, with significant market potential, though it is expected to launch in the latter half of 2028.
Negative Updates
Revenue Shortfall
Revenues of just over GBP 1 million for H1 2025 fell significantly below expectations, with full-year sales now expected to be between GBP 1.3 million and GBP 1.4 million, far below the initial GBP 5 million projection.
Read all updates
Q2-2025 Updates
Positive
Negative
R&D Developments
Futura is advancing two new products: Project Intense and WSD4000. Project Intense aims to enhance sensorial effects for men, with regulatory approval expected by the end of 2025. WSD4000 targets women's sexual response, with significant market potential, though it is expected to launch in the latter half of 2028.
Read all positive updates
Company Guidance
During the investor presentation call for Futura Medical plc, Interim CEO Alex Duggan provided guidance indicating that the company's full-year 2025 performance is expected to fall significantly below market expectations due to challenges in sustaining consumer uptake and lower-than-anticipated repeat sales. Despite launching in seven countries in H1, the initial strong trials did not translate into continued sales, affecting supply volumes and royalty streams. Angela Hildreth reported a revenue of just over GBP 1 million for the first half of 2025, with a gross profit of GBP 0.7 million, but also highlighted a GBP 0.49 million provision for inventory obsolescence. The company incurred an exceptional charge of GBP 3.6 million due to impairment of U.S. plant and equipment, contributing to a loss after tax of GBP 6.6 million. The adjusted loss after tax was GBP 1.9 million, with cash reserves at GBP 3.69 million at the period's end. Full-year sales for 2025 are now projected to be between GBP 1.3 million and GBP 1.4 million, with cash reserves reduced to GBP 2.7 million by the end of August. The company is actively exploring commercial and financing options to extend its cash runway, which currently runs into January 2026.Futura Medical Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
55
Neutral
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.70M | 13.93M | 3.10M | 0.00 | 0.00 |
| Gross Profit | 1.24M | 9.57M | 1.77M | -24.73K | -19.81K |
| EBITDA | -5.54M | 1.41M | -6.83M | -6.85M | -5.85M |
| Net Income | -9.07M | 1.29M | -6.51M | -5.85M | -4.96M |
Balance Sheet | |||||
| Total Assets | 5.22M | 13.59M | 11.82M | 6.47M | 11.80M |
| Cash, Cash Equivalents and Short-Term Investments | 3.40M | 6.60M | 7.71M | 4.03M | 10.37M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.41M | 4.63M | 6.34M | 1.75M | 2.08M |
| Stockholders Equity | 2.81M | 8.96M | 5.48M | 4.72M | 9.72M |
Cash Flow | |||||
| Free Cash Flow | -5.58M | -1.29M | -935.60K | -6.52M | -4.29M |
| Operating Cash Flow | -5.58M | 438.41K | 570.25K | -5.78M | -3.87M |
| Investing Cash Flow | 38.19K | -1.73M | -1.43M | -740.70K | -419.72K |
| Financing Cash Flow | 2.38M | 170.91K | 4.55M | 169.58K | 13.65M |
Futura Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | £53.59M | -9.39 | -55.47% | ― | ― | 19.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £344.28M | -8.36 | -2929.47% | ― | ― | ― | |
49 Neutral | £6.15M | -1.58 | -2.42% | ― | 34.02% | -93.85% | |
47 Neutral | £28.51M | -62.37 | -10.01% | ― | 95.16% | 85.60% | |
46 Neutral | £23.60M | 35.54 | -197.54% | ― | 3.31% | 21.91% | |
41 Neutral | £3.14M | -0.34 | -115.97% | ― | -87.82% | -746.51% |
* Healthcare Sector Average
GB:FUM
Futura Medical
0.54
-8.11
-93.73%
GB:AVCT
Avacta Group plc
73.00
40.50
124.62%
GB:OPTI
OptiBiotix Health
5.95
-6.05
-50.42%
GB:SBTX
SkinBioTherapeutics
11.50
-5.13
-30.83%
GB:POLB
Poolbeg Pharma Ltd.
7.60
4.30
130.30%
GB:AREC
Arecor Therapeutics PLC
62.50
19.00
43.68%
Futura Medical Corporate Events
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Futura Medical Sets June AGM and Publishes 2025 Annual Report
Positive
Jun 4, 2026
Futura Medical has scheduled its Annual General Meeting for 29 June 2026 in London and invited shareholders to participate either in person or via a range of proxy voting channels, with a deadline of 25 June for submitting remote votes. The compan...
Financial DisclosuresRegulatory Filings and Compliance
Futura Medical Updates Market on Block Listing and Share Option Balances
Neutral
Jun 1, 2026
Futura Medical has reported its latest six-monthly block listing update, covering the period from 9 December 2025 to 31 May 2026, for various employee and long-term incentive share schemes. During the period, 207,096 shares were allotted under the...
Business Operations and StrategyFinancial Disclosures
Futura Medical Swings to Loss as Eroxon Sales Lag and Cash Runway Tightens
Negative
Apr 29, 2026
Futura Medical reported a sharp deterioration in 2025 results, as revenue slid to £1.7 million from £13.9 million and the group swung to an operating loss of £9.1 million, reflecting slower-than-expected in-market sales and weak rep...
Business Operations and StrategyFinancial Disclosures
Futura Medical Sets Date for 2025 Results and Investor Webinar as Sexual Health Portfolio Expands
Positive
Apr 20, 2026
Futura Medical, the AIM-listed consumer healthcare group best known for its Eroxon erectile dysfunction gel, will publish full-year results for 2025 on 29 April and has scheduled an investor webinar the same day via the Investor Meet Company platf...
Business Operations and StrategyFinancial Disclosures
Futura Medical Sets Date for 2025 Results and Investor Webinar
Neutral
Apr 20, 2026
Futura Medical will publish its full-year results for 2025 on 29 April and will host an online investor presentation the same day via the Investor Meet Company platform. The webinar, open to existing and prospective shareholders, allows questions ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Futura Medical Reports Positive Home User Data for Eroxon and New Intense Formula
Positive
Mar 23, 2026
Futura Medical reported positive results from a four-week home user test comparing its marketed erectile dysfunction gel Eroxon with prototype formulation Eroxon Intense in 223 U.K. men, mostly with mild to moderate erectile dysfunction. Both prod...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.